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CHAPTER 8 
Pancreatic Transplantation Using the Duct Occlusion 
Technique 
W.D. ILLNER, D. ABENDROTH, R. LANDGRAF AND W. LAND 
Division of Transplant Surgery, Department of Surgery, Klinikum Grosshadem, 
Department of Internal Medicine nlnnenstadt"f University of Munich, Munich, West Germany 
Insulin-dependent diabetes mellitus leads to 
deleterious late vascular complications. This fact ac­
counts for higher morbidity and mortality compared to a 
non-diabetic population. Experimental studies (1, 2) 
proved and preliminary clinical data (3, 4) suggest that 
transplantation of the pancreas may prevent these late 
diabetic complications. Furthermore, since worldwide 
experience with pancreatic grafting has improved, we 
are encouraged to continue with human pancreas 
transplantation until the transplantation of isolated 
human islets becomes successful. 
The following report presents the Munich experience 
with the simultaneous transplantation of the pancreas 
and kidney using the duct occlusion technique with 
prolamine. We will also discuss our experience, though 
limited, with the sole transplantation of the pancreas in 
nonuremic patients. Parts of our experience have been 
published elsewhere (5). 
PATIENT SELECTION CRITERIA 
Two groups of patients with type I diabetes were ac­
cepted for pancreatic grafting: 
Group ArPatients with end-stage renal disease 
(These patients received a pancreas and a 
kidney simultaneously) 
Group B:Non-uremic diabetics with progressive 
retinopathy 
(These patients only received a pancreas 
transplant) 
Most of the patients in both groups suffered from 
other diabetic complications such as retinopathy, 
polyneuropathy and hypertension. Since 1985, patients 
with coronary heart disease or patients over 50 years of 
age have not been accepted for pancreatic grafting. 
METHODS 
Since 1979, we have performed 97 pancreas 
transplants in 93 diabetic patients. Eighty-six of these 
patients received a pancreas and a kidney simul­
taneously, 4 patients required retransplantation and 7 
who underwent an isolated transplantation of the 
pancreas had no signs of end-stage renal disease 
(Table 1). For the handling of exocrine secretion, we 
used the duct occlusion technique with prolamine ex­
clusively (5). 
Tablet. Number of segmental pancreatic 
allotransplants performed at the Munich 
Period No. Transplantation 
1979-1981 3 Pancreas and Kidney 
(Starting period) 
1981-8/1984 31 Pancreas + Kidney 
(Cyclosporine era) 1 Pancreas regrafts 
9/1984 - 8/1988 52 Pancreas + Kidney 
3 Pancreas regrafts 
7 Pancreas Alone 
Total: 97 
Organ Harvesting 
We only accepted organs from donors who were 10 
to 50 years of age with stable circulation and normal or 
subnormal endocrine and exocrine function. In ail 
cases, we harvested a segmental pancreas consisting 
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of the corpus and tail. For 
anastomoses we resected the 
coeliac axis and the portal vein. 
Recently, in cases of multiple 
organ transplantation, we used 
the mesenteric superior vein 
and the splenic artery in inter-
position with the Iliac artery of 
the donor. For the perfusion of 
the organs in situ, we used 
"Eurocollins" solution. Im-
munological selection was 
based upon blood group com-
patibility and a negative cross-
match. Tissue typing was then 
performed retrospectively. 
Duct Obliteration 
Procedure 
Prior to transplantation, the 
pancreatic duct was cannulated 
with a hypodermic needle. 
About 3-5 ml of occlusive substance, i.e. prolamine 
"EthiblocR" (Ethicon, Norderstedt, FRG) was injected 
under X-ray control. 
The duct obliteration was considered efficient when 
first signs of "over-injection" were verified on the X-ray 
(Fig. 1). Following occlusion, the ductal orifice and the 
parenchyma of the cut surface were ligated. The 
characteristics of prolamine are demonstrated in Table 
2. 
Recipient Operation 
The main surgical technique and postoperative 
management are shown in Table 3. From 1979 until 
1984, the graft was placed partly intra- and partly ex-
traperitoneally, as described by Dubernard, et al (6). 
Figure 1. Ex vivo approach of duct occlusion with prolamine. The duct 
injection is considered to be efficient when first signs of over-injection 
appear by x-ray. 
Table 2. Characteristics of prolamine. 
1. Solidifies rapidly in the duct system 
2. Is microbiologicaHy indifferent 
3. is reabsorbed within 2 weeks (in dogs) 
4. Leads to necrosis and regeneration of the duct epithelium 
5. Causes atrophy and fibrosis of the exocrine parenchyma 
6. is radiopaque 
7. Does not affect endocrine function 
Since September of 1984, grafts have been placed 
strictly intraperitoneally along the colon ascends. In the 
first 48 hours following transplantation, an abdominal ir-
rigation of 6 liter CAPD solution daily was carried out. 
The anastomoses of the vessels were managed by 
means of the end-to-side technique between the 
donor's coeliac axis and portal vein and the recipients 
external iliac vessels. Seven patients developed fatal 
bowel obstructions due to adhesions. These patients 
were treated without abdominal irrigation. 
Prolamine Complications 
In contrast to the animal experimental findings (7, 9) 
we have noted a more delayed destruction and atrophy 
of the exocrine parenchyma following duct occlusion 
with prolamine. During our experience 
with prolamine, every second patient 
developed a subcutaneous pancreatic fis-
tula (9) with a high incidence of secondary 
infection (complicated fistula). In order to 
prevent the pancreatic fistulae, we intro-
duced a strictly intraperitoneally position-
ing of the graft and an abdominal irriga-
tion. We hypothesized a reduction of the 
incidence of fistulae via reabsorption of 
the highly active amylase/lipase secre-
tions by the peritoneum. 
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Table 3. Surgical technique and postoperative management according to different periods. 
Period Surgical Anticoagulation Immunosuppressive Patient 
Technique therapy therapy Selection 
1979-9/1984 Extra-/lntra- "High" dose CsA plus CAD not 
Peritoneal Heparin Steroids excluded, 
Group I Positioning (PTT: 60 SEC.) Maintenance: Elderly pts 
CsA-Monotherapy Accepted 
n= 32 
9/1984-8/1988 Strictly Intra­ "Low* dose Triple/quadruple Exclusion 
peritoneal Heparin Drug of CAD 
Positioning (PTT: 40 sec.) Induction therapy (proven by 
arteriography) 
Group II Plus Plus Triple/ Pts > 50 years 
Abdomen.lavage Dextran40 Double drug Not accepted 
Maintenance therapy 
n= 52 (2 days) (CsA+AZA) 
A pilot study, however, proved that this approach 
was unsuccessful since there was no reduction in the 
incidences of fistulae. More recently we have used 
fibrin tissue adhesive which is applied to the organ sur­
face (10). The combination of the occlusion technique 
with the use of fibrin tissue adhesive and the abdominal 
irrigation actually seems to reduce the complications 
caused by transient exocrine secretions (Table 4). 
Postoperative Management 
Successful transplantation of the pancreas requires 
both a clear concept of postoperative management and 
the prevention of 2 major complications: the primary ir­
reversible venous thrombosis and the irreversible rejec­
tion of the organ. In our opinion, this can best be ac­
complished by effective immunosuppression and an-
ticoagulative measures for avoiding the risk of bleeding. 
The additional blocking of the exocrine function with 
"Somatostatin'1 may also be helpful. 
Table 4. Incidence of fistula formation in relation to applied 
surgical techniques. m 
I Extraperitoneal positioning of the graft 
II Intraperitoneal positioning of the graft 
III Intraperitoneal positioning of the graft, lavage 
IV Intraperitoneal positioning of the graft, lavage 
and tissue adhesive 
Anticoagulative Measures 
From 1979 to 1984, we only used heparin for an­
ticoagulation with a targeted PTT value of 60-80 
seconds. This regimen, however, induced severe 
hemorrhages requiring interventions. Since 1985, we 
have used a combined treatment of HDextranRw 40 and 
low-dose heparin, now targeting a PTT value of 40 
seconds. When comparing the high-dose and low-dose 
heparin protocols, the rates of venous thromboses did 
not differ statistically, although the frequency of bleeding 
complications was reduced significantly. 
Immunosuppressive Protocol 
With increasing experience using Ciclosporine 
(CsA), we have been confronted with the undesirable 
effects of this drug for it is associated with 
nephrotoxicity and has a narrow therapeutic range in 
terms of difficulty in achieving a maximum immunosup­
pressive effect with minimal 
nephrotoxicity. 
The alloreactivity reaches its maxi­
mum immediately posttransplant follow­
ing antigen exposition. As a conse­
quence, we initiated new therapeutic ap­
proaches to provide the highest possible 
immunosuppressive index using CsA in a 
non-nephrotoxic dosage regimen. At 
50%(n=32) 
70%(n=7) 
40%(n=16) 
20%(n=20) 
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Table 5. Immunosuppressive protocol in 
pancreatic transplantation 
Table 6. Pancreas graft loss following 
simultaneous pancreas and kidney 
Induction Therapy: Quadruple Drug 
CsA: 1 mg/ b.w. i.v. via perfusor/24h 
2-1 mg/b.w. 
500 mg/day MP initially, tapered to 
30 mg/day within 1 week 
4 mg/ 20 mg/b/w/ for 10 days or 
5 mg/day for 10 days 
CsA + AZA + Steroids 
for 6 months 
Double drug 
(CsA + AZA) 
AZA: 
Steroids: 
ATG/ALG: 
OKT3: 
Triple-drug maintenance: 
Maintenance therapy: 
(Period: 9/1984-8/1988) n=52 
Venous thrombosis 15% (n-8) 
Infected fistula 12% (n=6) 
Parenchymal bleeding 2% (n-1) 
Acute rejection 10% (n=5) 
Chronic rejection 6% (n=3) 
Patient death 2% (n=1) 
present our group has an established immunosuppres-
sive protocol (Table 5) as follows: 
Quadruple drug induction therapy; triple-drug main-
tenance treatment CsA, azathioprine (AZA), and 
steroids over a period of 6 months postoperatively then 
double-drug maintenance therapy (CsA, AZA) beyond 6 
months posttransplant. 
To date, 52 patients with simultaneous pancreas and 
kidney transplants have been treated according to the 
above mentioned regimen. The preliminary data are 
promising and have been published in Gothenburg (11). 
The overall losses of pancreas grafts are shown in 
Table 6. 
posttransplant was 48% for the pancreas and 70% for 
the kidney (Fig. 3). 
All survival rates were estimated by the com-
puterized probability formula of Cutler/Ederer (12). 
The results in patients receiving an isolated 
pancreas transplant were poor. Graft loss due to acute 
irreversible rejection was observed in 2 cases, progres-
sive rejection was noted in 1 and 4 grafts were lost due 
to primary irreversible thrombosis. 
Metabolic Studies 
The endocrine function of the pancreas will sub-
sequently be investigated in all successfully grafted 
patients with an oral glucose load and arginine-stimula-
tion. None of the successfully transplanted patients re-
RESULTS 
Patients were divided into 2 
groups: 
Group I: Patients who received 
a transplant between 
1979 and August 
1984. 
Group ll:Patients who received 
a transplant between 
August 1984 and 
August 1988. 
The patient survival rate in 
Group I was 82%. The graft 
function rates 3-years post-
transplant were 25% for the 
pancreas and 33% for the kid-
ney (Fig. 2). 
The patient survival rate in 
Group II was 98% . The graft 
function rate 4-years 
Simultaneous Pancreas+Kidn^ 
(Group I n«32) " 
1981-8/84 
Months 
Figure 2. Patient and graft survival in simultaneous pancreas and 
kidney transplantation from 1981-8/1984. (Cutler/Ederer formula) 
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Figure 3. Patient and graft survival in simultaneous pancreas and 
kidney transplantation. According to modified surgical technique, 
immunosuppressive and anticoagulation therapy (9/1984 - 8/1988). 
100g Glucose p.e. 15gAfgininel.v. 
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Figure 4. Behavior of blood glucose and serum insulin during oral 
glucose load and Lv. arginine stimulation (shaded area) according to 
different posttransplant periods in simultaneously transplanted patients. 
quired exogenous insulin, all 
showed a normal glycosylated 
hemoglobin and 71% 
presented with normal oral 
glucose tolerance. 
The remaining 29% of the 
successfully transplanted 
patients had impaired glucose 
disposal with lower and 
delayed insulin release. The 
most important observation 
regarding the technique used 
for duct occlusion was that in 
the long run, no deterioration of 
the endocrine function occurred 
(Fig. 4). 
Ophthalmologics! 
and Neurological 
Observations 
In 56% of 34 investigated 
patients, visual acuity im­
proved. Stabilization was 
noted in 32% and deterioration 
was only observed in 12%. A 
regression and/or stabilization 
of vascular proliferation was 
observed in 88% whereas a 
progression occurred in 12% of 
the cases. 
However, vitreous hemor­
rhage was reduced from 69% 
prior to transplantation to 24% 
posttransplant. In 28 patients 
observed, subjective signs of 
polyneuropathy such as pares­
thesias, hyper- and hypos-
thesia, restless legs or muscle 
weakness disappeared in 46%. 
No deterioration was observed. 
Sensory or motor nerve con­
duction velocity improved in 
71% whereas no change oc­
curred in 28% of the cases and 
no deterioration was observed. 
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Peripheral Microcirculation 
To evaluate the influence of pancreas grafting on 
peripheral microcirculation, we measured the 
transcutaneous oxygen pressure (tcp02) and used 
telethermography (14). 
The data from 18 patients showed a significant rise 
of tcp02 from values of 44 ± 2mm Hg pretransplant to 
63 ± 4mm Hg posttransplant. The thermographic pat-
tern also revealed a significant increase: the skin-
temperature measured on the forefeet was +1.92 ± 
0.07°C compared to 0.36 ± 0.020 °C in the non-diabetic 
kidney grafted patients. 
SUMMARY 
Since 1979, the Munich Group has gathered ex-
perience with 100 consecutive pancreas transplants 
using the duct occlusion technique. At the present 
time, 40 of the pancreas grafts (44%) and 56 of the 
renal grafts (65%) of 90 patients who received both a 
pancreas and a kidney are still functioning. 
The mortality rate of 18% in the early period was 
relatively high. In the period from 1984 until 1988-
using the simple transplantation technique - only one 
patient died. During this period, our overall results 
improved with the use of a modified surgical techni-
que and different immunosuppressive and an-
ticoagulative measures along with better patient 
selection. Normalization of the glucose metabolism 
seems to improve the rate of late diabetic complica-
tions. The duct occlusion technique in isolated 
pancreas transplants might have been a disad-
vantage in accounting for the poor results. 
With regard to metabolic studies, there is now 
ample evidence to suggest that successful 
pancreatic transplantation leads to complete nor-
malization of glucose metabolism including nor-
moglycemia in more than 70% of all patients. 
In addition, clinical data are accumulating that 
suggest successful pancreatic transplantation has a 
beneficial effect on the late secondary syndrome of 
Type I diabetes mellitus. 
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